These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20961395)

  • 1. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.
    Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M
    J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
    Semeraro F; Ammollo CT; Semeraro N; Colucci M
    Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
    J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
    Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
    J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
    Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
    J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
    Develter J; Booth NA; Declerck PJ; Gils A
    J Thromb Haemost; 2008 Nov; 6(11):1884-91. PubMed ID: 18752580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG; Kirklin JK
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography.
    Katori N; Tanaka KA; Szlam F; Levy JH
    Anesth Analg; 2005 Jun; 100(6):1781-1785. PubMed ID: 15920213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
    Von dem Borne PA; Bajzar L; Meijers JC; Nesheim ME; Bouma BN
    J Clin Invest; 1997 May; 99(10):2323-7. PubMed ID: 9153272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots.
    Collet JP; Montalescot G; Lesty C; Weisel JW
    Circ Res; 2002 Mar; 90(4):428-34. PubMed ID: 11884372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.
    Suzuki Y; Sano H; Mochizuki L; Honkura N; Urano T
    Blood Adv; 2020 Nov; 4(21):5501-5511. PubMed ID: 33166409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
    Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
    Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
    Stubblefield WB; Alves NJ; Rondina MT; Kline JA
    PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG; Steenwyk BL; Gurley WQ
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.